Photo by nci from unsplash
Women with heart failure (HF) are under‐represented in individual randomized clinical trials (RCTs). Little is known about sex‐specific treatment effects in HF medications. We evaluated sex differences in the response… Click to show full abstract
Women with heart failure (HF) are under‐represented in individual randomized clinical trials (RCTs). Little is known about sex‐specific treatment effects in HF medications. We evaluated sex differences in the response to mineralocorticoid receptor antagonists (MRAs) in major HF MRA trials, including a broad spectrum of left ventricular ejection fraction (LVEF).
Keywords:
sex differences;
mineralocorticoid receptor;
sex;
differences mineralocorticoid;
clinical trials
Journal Title: European Journal of Heart Failure
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Heart Failure
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!